Reference — Pharmacology
High-Alert Medications
High-alert medications are drugs that bear a heightened risk of causing significant patient harm when used in error. The Institute for Safe Medication Practices (ISMP) maintains a list of these medications and advocates for additional safeguards in their handling, preparation, and administration.
Educational use only. This reference is for clinical learning. High-alert medication protocols, double-check requirements, and approved formularies vary by facility. Always follow your institution's specific policies. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
What Makes a Medication High-Alert?
High-alert medications are not necessarily the most frequently associated with errors — they are the medications where errors are most likely to cause serious or fatal harm. The category reflects harm potential, not frequency of error.
Common characteristics of high-alert medications:
- Narrow therapeutic index (small margin between therapeutic and toxic doses)
- Risk of cardiovascular, respiratory, or neurological collapse if given incorrectly
- Look-alike / sound-alike names or similar packaging to other products
- Complex calculations or preparation requirements
- Need for ongoing laboratory or clinical monitoring
ISMP High-Alert Categories — Nursing Safety Considerations
Anticoagulants
Examples: Heparin (unfractionated and low molecular weight), warfarin, direct oral anticoagulants (apixaban, rivaroxaban, dabigatran), argatroban
Primary risks: Uncontrolled bleeding, hemorrhagic stroke, heparin-induced thrombocytopenia (HIT)
Nursing safety considerations:
- Verify weight-based dosing calculations independently
- Monitor PTT (heparin) or INR (warfarin) closely
- Assess for bleeding (urine, stool, bruising, neurological changes)
- Know reversal agents: protamine sulfate (heparin), vitamin K / FFP (warfarin), idarucizumab (dabigatran), andexanet alfa (Factor Xa inhibitors)
Insulin
Examples: All insulin types: rapid-acting (lispro, aspart), short-acting (regular), intermediate (NPH), long-acting (glargine, detemir)
Primary risks: Hypoglycemia (can be rapid and life-threatening), hyperglycemia from omission
Nursing safety considerations:
- Independent double check required for all insulin doses at most facilities
- Verify concentration (U-100 standard; U-500 requires special precautions)
- Match insulin type and timing to ordered meal plan
- Have glucose source available; know hypoglycemia treatment (15-15 rule)
- Check blood glucose before administration per orders
Opioids
Examples: Morphine, oxycodone, hydromorphone, fentanyl, methadone, codeine, tramadol
Primary risks: Respiratory depression, sedation, apnea, death
Nursing safety considerations:
- Assess respiratory rate, sedation level, and pain before each dose
- Independent double check for IV infusions and PCA loading doses
- Have naloxone immediately available for IV opioid administration
- Monitor for oversedation using a validated sedation scale (e.g., POSS, RASS)
- Use the lowest effective dose; titrate carefully in opioid-naive patients
Concentrated Electrolytes
Examples: Potassium chloride (IV concentrate), hypertonic saline (3%), magnesium sulfate IV, calcium chloride IV
Primary risks: Cardiac arrest, fatal dysrhythmia, cerebral edema
Nursing safety considerations:
- Concentrated KCl (> 10 mEq/100 mL) should never be stored on patient care units without pharmacy preparation
- Hypertonic saline requires ICU-level monitoring; correct sodium too rapidly can cause osmotic demyelination syndrome
- Cardiac monitoring required during IV potassium and magnesium infusions
- IV calcium and IV phosphate must not infuse through the same IV line — will precipitate
Neuromuscular Blocking Agents
Examples: Succinylcholine, rocuronium, vecuronium, cisatracurium
Primary risks: Complete respiratory paralysis — fatal without immediate ventilatory support
Nursing safety considerations:
- Must be stored separately from other medications; many facilities require red warning labels
- Only used in settings with immediate intubation capability and airway support
- Patient is completely unable to breathe — ventilator management is mandatory
- Reversal: sugammadex reverses rocuronium/vecuronium; succinylcholine has no reversal agent
Chemotherapy / Antineoplastics
Examples: Methotrexate, vincristine, cyclophosphamide, cisplatin (and all cytotoxic agents)
Primary risks: Severe immunosuppression, organ toxicity, death from overdose or incorrect route
Nursing safety considerations:
- Preparation, dispensing, and administration require specialized training and PPE
- Vincristine is never administered via intrathecal route — sentinel event category
- Double-check protocols and pharmacist verification required before administration
- Patient education on handling body fluids during and after treatment
Vasoactive / Cardiovascular Agents
Examples: Epinephrine, norepinephrine, dopamine, vasopressin, dobutamine, amiodarone, digoxin
Primary risks: Severe hypertension, hypotension, fatal dysrhythmia
Nursing safety considerations:
- Continuous cardiac monitoring required for all IV vasoactive infusions
- Smart pump drug library with dose limits should always be used
- Titrate slowly; document rationale for every dose change
- Know antidotes: atropine for bradycardia, calcium / digoxin immune Fab for digoxin toxicity
Sedatives / Hypnotics
Examples: Propofol, dexmedetomidine, ketamine, midazolam, lorazepam
Primary risks: Respiratory depression, paradoxical agitation, hemodynamic instability
Nursing safety considerations:
- Propofol requires intensive monitoring (ICU or procedural sedation setting)
- Benzodiazepines in elderly patients increase fall and delirium risk significantly
- Monitor sedation level continuously during IV infusion
- Reversal: flumazenil reverses benzodiazepines (short-acting; re-sedation risk)
Related Guides & Charts
Standards & sources
Fact-checked Jun 20, 2026This page is written to align with Institute for Safe Medication Practices (ISMP) · FDA prescribing information · The Joint Commission — National Patient Safety Goals. It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →